April 3, 2012
Pfizer Japan announced on March 30 that the company received on the same day marketing approval for its Xalkori Capsule 200 mg, 250 mg (crizotinib) for the treatment of anaplastic lymphoma kinase (ALK) fusion gene-positive advanced non-small cell lung cancer...read more